Approval Package for:

APPLICATION NUMBER:
ANDA 74-703/S-006

Name: Metoclopramide Oral Solution USP, 5 mg/5 mL

Sponsor: Morton Grove Pharmaceuticals, Inc.

Approval Date: June 30, 2009
**CONTENTS**

<table>
<thead>
<tr>
<th>Reviews / Information Included in this Review</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Tentative Approval Letter</td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td>X</td>
</tr>
<tr>
<td>Labeling Reviews</td>
<td>X</td>
</tr>
<tr>
<td>Medical Reviews</td>
<td>X</td>
</tr>
<tr>
<td>Chemistry Reviews</td>
<td></td>
</tr>
<tr>
<td>Bioequivalence Reviews</td>
<td></td>
</tr>
<tr>
<td>Other Reviews</td>
<td>X</td>
</tr>
<tr>
<td>Microbiology Reviews</td>
<td></td>
</tr>
<tr>
<td>Administrative &amp; Correspondence Documents</td>
<td>X</td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:
ANDA 74-703/S-006

APPROVAL LETTER
Dear Dr. Hodosh:

Please refer to your supplemental new drug application submitted under section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Metoclopramide Oral Solution USP, 5 mg/5 mL.

We acknowledge receipt of your submissions dated March 26, April 16, May 12, June 10, and June 26, 2009.

Reference is also made to our letter dated February 26, 2009 notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for Metoclopramide Oral Solution USP, 5 mg/5 mL. This information pertains to the risk of tardive dyskinesia.

This supplemental new drug application provides for revisions to the labeling for Metoclopramide Oral Solution USP, 5 mg/5 mL consistent with our February 26, 2009, letter and correspondences between FDA and Morton Grove dated May 6, and June 8, 2009.

We have completed our review of this supplemental application, as amended, and it is approved.

Your approved Medication Guide will become part of the Risk Evaluation and Mitigation Strategy (REMS) in pending supplement ANDA 74-703/S-007.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling (21 CFR 314.50(1)) in structured product labeling (SPL) format as described at [http://www.fda.gov/oc/datacouncil/spl.html](http://www.fda.gov/oc/datacouncil/spl.html) that is identical to the attached labeling and Medication Guide.
Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "SPL for approved ANDA 74-703/S-006." In addition, within 21 days of the date of this letter, amend any pending supplement for this ANDA.

We request that the revised labeling approved today be available on your website within 10 days of receipt of this letter.

Marketing the product with FPL that is not identical to the approved labeling and in the required format may render the product misbranded and an unapproved generic drug.

Please note that:

- this Medication Guide must be reprinted immediately following the last section of labeling or, alternatively, accompany the prescription drug labeling [21 CFR 201.57(c)(18) or 21 CFR 201.80(f)(2)];

- you are responsible for ensuring that this Medication Guide is available for distribution to every patient who is dispensed a prescription for this product [21 CFR 208.24];

- the final printed Medication Guide distributed to patients must conform to all conditions described in 21 CFR 208.20, including a minimum of 10 point text; and

- you are responsible for ensuring that the label of each container or package includes a prominent and conspicuous instruction to authorized dispensers to provide a Medication Guide to each patient to whom the drug is dispensed, and states how the Medication Guide is provided [21 CFR 208.24(d)]

**LETTER TO HEALTH CARE PROFESSIONALS**

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this ANDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved ANDA (21 CFR 314.80 and 314.81).
If you have any questions, please contact Sarah Park, Labeling Reviewer, at (240) 276-8995.

Sincerely,

{See appended electronic signature page}

Gary Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research

Enclosure: Package Insert and Medication Guide
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Gary Buehler
6/30/2009 05:51:27 PM
APPLICATION NUMBER:
ANDA 74-703/S-006

LABELING
Each 5 mL (teaspoonful) contains:

Metoclopramide, USP . . . . . . . . . . . . . . . . . . . . . 5 mg (present as the hydrochloride)

Alcohol . . . . . . . . . . . . . . . . . . . . . . . . less than 0.1%

In an orange-colored, palatable, aromatic, sugar-free vehicle.

USUAL DOSAGE: See accompanying insert.

WARNINGS: KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.

In case of accidental overdose, seek professional assistance or contact a Poison Control Center immediately.

Store at controlled room temperature, between 20 ˚C and 25 ˚C (68 ˚F to 77 ˚F) (see USP).

Protect from freezing. Dispense in a tight, light-resistant container as defined in the USP, with child-resistant closure.

Manufactured For: Wockhardt USA, LLC

Parsippany, NJ 07054

Manufactured By: Morton Grove Pharmaceuticals, Inc.

Morton Grove, IL 60053

A50-7622-16 REV. 05-09

NDC 60432-622-16

METOCLOPRAMIDE ORAL SOLUTION, USP

5 mg/5 mL

Alcohol less than 0.1%

Rx Only

NET: 1 Pint (473 mL)

DO NOT USE IF INNER FOIL SEAL PRINTED “SEALED FOR YOUR PROTECTION” IS BROKEN OR MISSING.

Please dispense with medication guide.

Rx Only

NET: 1 Pint (473 mL)

APPROVED BY ______________________________

DATE _________________

This color proof or PDF is a representation of the colors and will not reflect the final press output.

This is a *REVISED FILE

*REVISED FILES REQUIRE A “DISPOSITION APPROVAL” SIGNATURE. UNI-LABEL & TAG CAN NOT RELEASE THE “APPROVED” “REVISED” ART WITH OUT THIS SIGNATURE.

It is important that OLD computer files/disks, art, artificial butterscotch flavor, natural & artificial H2NOCH t1/2(hr)5 to 6 (present as the hydrochloride).

The antiemetic properties of metoclopramide appear to be a result of its Symptomatic Gastroesophageal Reflux

There have been rare reports of an uncommon but potentially fatal symptom complex sometimes referred to as Neuroleptic... of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).

INDICATIONS AND USAGE

The use of Metoclopramide Oral Solution is recommended for 5680 mcg/L. The mean elimination half-life, clearance, and volume of distribution is high (about 3.5 L/kg) which suggests extensive distribution of drug to the tissues. Similarly, continuous ambulatory peritoneal dialysis does not significantly alter the elimination elimination of metoclopramide.

p8

p9

p10

p11

p12

p13

This color proof or PDF is a representation of the colors and will not reflect the final press output.

DISPOSITION

PROOF DOCUMENTATION

PROOF DOCUMENTATION

RESPONSE REQUIRED

BARCODE

Signature

Date

Date

Date

Date
Metoclopramide Oral Solution, USP 5 mg/5 mL

**Medication Guide**

**Metoclopramide (met-o-KLO-pra-mide)**

Read the Medication Guide that comes with Metoclopramide before you start taking it and each time you get a refill. There may be new information. If you take another product that contains metoclopramide (such as REGLAN tablets, REGLAN ODT, or REGLAN injection), you should read the Medication Guide that comes with that product. Some of the information may be different. This Medication Guide does not take the place of talking with your doctor about your medical condition or your treatment.

**What is the most important information I should know about Metoclopramide?**

Metoclopramide can cause serious side effects, including:

- Abnormal muscle movements called tardive dyskinesia (TD). These movements happen mostly in the face muscles. You can not control these movements. They may not go away even after stopping Metoclopramide. There is no treatment for TD, but symptoms may lessen or go away over time after you stop taking Metoclopramide.
- Your chances for getting TD go up:
  - the longer you take Metoclopramide and the more Metoclopramide you take. You should not take Metoclopramide for more than 12 weeks.
  - if you are older, especially if you are a woman
  - if you have diabetes
- It is not possible for your doctor to know if you will get TD if you take Metoclopramide.

Tell your doctor right away if you get these movements. You can not stop or control, they may not go away even after stopping Metoclopramide. Metoclopramide may cause your body to hold fluids. It is not possible for your doctor to know if you will get TD if you take Metoclopramide.

**Who should not take Metoclopramide?**

Do not take Metoclopramide if you:
- have stomach or intestine problems that could get worse with Metoclopramide, such as bleeding, blockage, or a tear in the stomach or bowel wall
- have an adrenal gland tumor called a pheochromocytoma
- are allergic to Metoclopramide or anything in it. See the end of this Medication Guide for a list of the ingredients in Metoclopramide.
- take medicines that can cause uncontrolled movements, such as medicines for mental illness
- have seizures

Tell your doctor about all your health problems, including:
- depression
- Parkinson’s disease
- high blood pressure
- kidney problems. Your doctor may start with a lower dose.
- liver problems or heart failure. Metoclopramide may cause your body to hold fluids.
- diabetes. Your dose of insulin may need to be changed.
- breast cancer
- you are pregnant or plan to become pregnant. It is not known if Metoclopramide will harm your unborn baby.
- you are breast-feeding. Metoclopramide can pass into breast milk and may harm your baby.

Call your doctor right away if you get movements you can not stop or control, such as:
- lip smacking, chewing, or puckering up your mouth
- frowning or scowling
- sticking out your tongue
- blinking and moving your eyes
- shaking of your arms and legs

See the section “What are the possible side effects of Metoclopramide?”

**What is Metoclopramide?**

Metoclopramide is a prescription medicine used:
- in adults for 4 to 12 weeks to relieve heartburn symptoms with gastroesophageal reflux disease (GERD) when certain other treatments do not work. Metoclopramide relieves daytime heartburn and heartburn after meals. It also helps ulcers in the esophagus to heal.
- to relieve symptoms of slow stomach emptying in people with diabetes. Metoclopramide helps treat symptoms such as nausea, vomiting, heartburn, feeling full long after a meal, and loss of appetite. All these symptoms do not get better at the same time.

It is not known if Metoclopramide is safe and works in children.

**What should I tell my doctor before taking Metoclopramide?**

Tell your doctor about all your health problems, including:
- depression
- Parkinson’s disease
- high blood pressure
- kidney problems. Your doctor may start with a lower dose.
- liver problems or heart failure. Metoclopramide may cause your body to hold fluids.
- diabetes. Your dose of insulin may need to be changed.
- breast cancer
- you are pregnant or plan to become pregnant. It is not known if Metoclopramide will harm your unborn baby.
- you are breast-feeding. Metoclopramide can pass into breast milk and may harm your baby.

Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Metoclopramide and some other medicines may interact with each other and may not work as well, or cause possible side effects. Do not start any new medicines while taking Metoclopramide until you talk with your doctor.

Tell your doctor if you take:
- another medicine that contains Metoclopramide, such as REGLAN tablets, REGLAN ODT.
- a blood pressure medicine
- a medicine for depression, especially an Monoamine Oxidase Inhibitor (MAOI)
- insulin
- a medicine that can make you sleepy, such as anti-anxiety medicine, sleep medicines, and narcotics.

If you are not sure if your medicine is one listed above, ask your doctor or pharmacist.

Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.

**How should I take Metoclopramide?**

- Take Metoclopramide in the amount prescribed by your doctor.
- Take your medicine at the same time each day.
- Take Metoclopramide before you start taking it and each time you get a refill. There may be new information. If you take another product that contains metoclopramide (such as REGLAN tablets, REGLAN ODT, or REGLAN injection), you should read the Medication Guide that comes with that product. Some of the information may be different. This Medication Guide does not take the place of talking with your doctor about your medical condition or your treatment.

**What is the most important information I should know about Metoclopramide?**

Metoclopramide can cause serious side effects, including:

- Abnormal muscle movements called tardive dyskinesia (TD). These movements happen mostly in the face muscles. You can not control these movements. They may not go away even after stopping Metoclopramide. There is no treatment for TD, but symptoms may lessen or go away over time after you stop taking Metoclopramide.
- Your chances for getting TD go up:
  - the longer you take Metoclopramide and the more Metoclopramide you take. You should not take Metoclopramide for more than 12 weeks.
  - if you are older, especially if you are a woman
  - if you have diabetes
- It is not possible for your doctor to know if you will get TD if you take Metoclopramide.

Tell your doctor right away if you get these movements. You can not stop or control, they may not go away even after stopping Metoclopramide. Metoclopramide may cause your body to hold fluids. It is not possible for your doctor to know if you will get TD if you take Metoclopramide.

**Who should not take Metoclopramide?**

Do not take Metoclopramide if you:
- have stomach or intestine problems that could get worse with Metoclopramide, such as bleeding, blockage, or a tear in the stomach or bowel wall
- have an adrenal gland tumor called a pheochromocytoma
- are allergic to Metoclopramide or anything in it. See the end of this Medication Guide for a list of the ingredients in Metoclopramide.
- take medicines that can cause uncontrolled movements, such as medicines for mental illness
- have seizures

Tell your doctor about all your health problems, including:
- depression
- Parkinson’s disease
- high blood pressure
- kidney problems. Your doctor may start with a lower dose.
- liver problems or heart failure. Metoclopramide may cause your body to hold fluids.
- diabetes. Your dose of insulin may need to be changed.
- breast cancer
- you are pregnant or plan to become pregnant. It is not known if Metoclopramide will harm your unborn baby.
- you are breast-feeding. Metoclopramide can pass into breast milk and may harm your baby.

Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Metoclopramide and some other medicines may interact with each other and may not work as well, or cause possible side effects. Do not start any new medicines while taking Metoclopramide until you talk with your doctor.

Tell your doctor if you take:
- another medicine that contains Metoclopramide, such as REGLAN tablets, REGLAN ODT.
- a blood pressure medicine
- a medicine for depression, especially an Monoamine Oxidase Inhibitor (MAOI)
- insulin
- a medicine that can make you sleepy, such as anti-anxiety medicine, sleep medicines, and narcotics.

If you are not sure if your medicine is one listed above, ask your doctor or pharmacist.

Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.
How should I take Metoclopramide?
- Take Metoclopramide exactly as your doctor tells you. Do not change your dose unless your doctor tells you.
- You should not take Metoclopramide for more than 12 weeks.
- If you take too much Metoclopramide, call your doctor or Poison Control Center right away.

What should I avoid while taking Metoclopramide?
- Do not drink alcohol while taking Metoclopramide. Alcohol may make some side effects of Metoclopramide worse, such as feeling sleepy.
- Do not drive, work with machines, or do dangerous tasks until you know how Metoclopramide affects you.
- Metoclopramide may cause sleepiness.

What are the possible side effects of Metoclopramide?
Metoclopramide can cause serious side effects, including:
- Abnormal muscle movements. See “What is the most important information I should know about Metoclopramide?”
- Uncontrolled spasms of your face and neck muscles, or muscles of your body, arms, and legs (dystonia). These muscle spasms can cause abnormal movements and body positions. These spasms usually start within the first 2 days of treatment. These spasms happen more often in children and adults under age 30.
- Depression, thoughts about suicide, and suicide. Some people who take Metoclopramide become depressed. You may have thoughts about hurting or killing yourself. Some people who take Metoclopramide have ended their own lives (suicide).
- Neuroleptic Malignant Syndrome (NMS). NMS is a very rare but very serious condition that can happen with Metoclopramide. NMS can cause death and must be treated in a hospital. Symptoms of NMS include: high fever, stiff muscles, problems thinking, very fast or uneven heartbeat, and increased sweating.
- Parkinsonism. Symptoms include slight shaking, body stiffness, trouble moving or keeping your balance. If you already have Parkinson’s disease, your symptoms may become worse while you are receiving Metoclopramide.

Call your doctor and get medical care right away if you:
- feel depressed or have thoughts about hurting or killing yourself
- have high fever, stiff muscles, problems thinking, very fast or uneven heartbeat, and increased sweating
- have muscle movements you can not stop or control
- have muscle movements that are new or unusual

Common side effects of Metoclopramide include:
- feeling restless, sleepy, tired, dizzy, or exhausted
- headache
- confusion
- trouble sleeping
You may have more side effects the longer you take Metoclopramide and the more Metoclopramide you take.
You may still have side effects after stopping Metoclopramide. You may have symptoms from stopping (withdrawal) Metoclopramide such as headaches, and feeling dizzy or nervous. Tell your doctor about any side effects that bother you or do not go away. These are not all the possible side effects of Metoclopramide. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store Metoclopramide?
- Store Metoclopramide at room temperature, 68°F to 77°F (20°C to 25°C).
- Keep Metoclopramide in the bottle it comes in. Keep the bottle closed tightly.
- Do not freeze Metoclopramide.

Keep Metoclopramide and all medicines out of the reach of children.

General information about Metoclopramide:
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Metoclopramide for a condition for which it was not prescribed. Do not give Metoclopramide to other people, even if they have the same symptoms you have. It may harm them.

This Medication Guide summarizes the most important information about Metoclopramide. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about Metoclopramide that is written for healthcare professionals. For more information, go to www.wockhardtusa.com or call 1-800-346-6854

What are the ingredients in Metoclopramide?
Active ingredient: Metoclopramide
Active ingredient: Metoclopramide
Inactive ingredients: artificial butterscotch flavor, natural & artificial apple flavor, citric acid anhydrous, FD&C Yellow No. 6, gelatin, methylparaben, propylene glycol, propylparaben, purified water and sorbitol solution. It may contain 10% citric acid solution or 10% sodium citrate solution for pH adjustment.

Product No.: 7622
Manufactured For: Wockhardt USA, LLC Parsippany, NJ 07054
Manufactured By: Morton Grove Pharmaceuticals, Inc. Morton Grove, IL 60053

This Medication Guide has been approved by the U.S. Food and Drug Administration.

27622A ISS. 07-09
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
ANDA 74-703/S-006

LABELING REVIEWS
Labeling Supplement Review

Application Number: 74-703/S-006

Name of Drug: Metoclopramide Oral Solution USP, 5 mg/5 mL

Applicant: Morton Grove Pharmaceuticals, Inc.

Material Reviewed: (specify labeling pieces)

<table>
<thead>
<tr>
<th>Submission Date(s):</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>March 26, 2009</td>
<td>Prior Approval Supplement submission: Proposed insert with container label attached and medication guide</td>
</tr>
<tr>
<td>April 16, 2009</td>
<td>proposed REMS</td>
</tr>
<tr>
<td>May 12, 2009</td>
<td>insert with container label attached and medication guide in final print</td>
</tr>
<tr>
<td>June 10, 2009</td>
<td>Medication Guide in final print</td>
</tr>
<tr>
<td>June 26, 2009</td>
<td>insert with container label attached and medication guide in final print</td>
</tr>
</tbody>
</table>

Background and Summary

1. Background:
On February 26, 2009, an IR letter was sent to the firm under section 505(o)(4) of the FDCA to require safety related label changes to the labeling of Metoclopramide Oral Solution USP, 5 mg/5 mL to address the risk of tardive dyskinesia associated with the use of this products based on new safety information about this risk. Firm was asked to make safety labeling changes to the insert and propose a Medication Guide. Firm was also asked to propose a Risk Evaluation and Mitigating Strategy (REMS).

2. This supplemental application provides for revisions to the labeling for Metoclopramide Oral Solution USP, 5 mg/5 mL consistent with our February 26, 2009, letter and correspondences between FDA and Morton Grove dated May 6, June 8, and June 24, 2009.

3. This ANDA is the RLD.
Previous RLD (currently discontinued in the Orange Book) was NDA 18-821, Reglan Syrup, which was withdrawn on November 12, 2002. RLD for the tablet dosage form is Reglan Tablets, NDA 17-854/S-017 approved July 26, 2004.

Review

1. Professional Insert was reviewed by Dr. Christopher Leptak, Medical Officer, of the Division of Gastroenterology Products, and found acceptable.

2. The Medication Guide was reviewed by Dr. Tamara Johnson, Medical Officer, of the Division of Gastroenterology Products and found acceptable.

3. REMS was consulted to OSE and reviewed by Mary Dempsey, Risk Management Program Coordinator (DRISK). The REMS review signed on June 24, 2009 recommends comments to be communicated to the firm. The REMS will not be approved at this time.

4. The container label is same as the previously approved label, except the following:
   • Addition of a statement “PHARMACIST: PLEASE DISPENSE WITH MEDICATION GUIDE.” to the principal display panel.
   • Addition of a statement “Manufactured for: Wockhardt USA, LLC Parispanny, NJ 07054” to the side panel.

Recommendation

The submitted labels and labeling are acceptable with comments.

INSERT with CONTAINER label attached:
Satisfactory in final print as submitted in the June 26, 2009 e-submission.

Medication Guide
Satisfactory in final print as submitted in the June 26, 2009 e-submission.

COMMENT TO FIRM:

INSERT

INDICATIONS AND USAGE, Gastroesophageal Reflux – revise the first sentence to read “...adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy.”

{see appended electronic signature}
Sarah Park
Labeling Reviewer

Supervisory Comment/Concurrence:

{see appended electronic signature}
Koung Lee
Team Leader
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
Soojung Sarah Park
6/30/2009 03:23:08 PM
LABELING REVIEWER

Koung Lee
6/30/2009 03:37:44 PM
LABELING REVIEWER
For Wm Peter Rickman - Labeling reviewer will inform the firm to increase the font size of the Medication Guide form 9.25 pts to at least 10 pts.
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
ANDA 74-703/S-006

MEDICAL REVIEWS
July 17, 2009

The attached review due to an editing error has some incorrect information on page 5 under the heading “Consults” and misrepresented DDMAC and DRISK comments. This error has been corrected in the subsequent Clinical Review signed by Christopher Leptak, MD dated 7 July, 2009 titled "Amended Tardive Dyskinesia Clinical Review of Pls."
Christopher Leptak, MD., PhD.,  
NDAs 17-854, 17-862, and 21-793. ANDAs 71-402, 72-744, 73-680, and 74-703  
Tardive dyskinesia class-labeling for metoclopramide-containing products

<table>
<thead>
<tr>
<th><strong>CLINICAL REVIEW</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Application Type</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Application Number(s)</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Submit Date(s)</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Received Date(s)</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Amended PDUFA Goal Date</strong></td>
</tr>
<tr>
<td>(Original PDUFA date prior to two extensions to harmonize the timing of the class labeling submissions and product reviews: April 17, 2009)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Reviewer Name(s)</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Review Completion Date</strong></td>
</tr>
<tr>
<td><strong>Therapeutic Class</strong></td>
</tr>
<tr>
<td><strong>Indication(s)</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Intended Population(s)</strong></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

1 Reglan injection (NDA 17-862) is not indicated for relief of symptomatic GERD. Additional indications for Reglan injection are prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, prevention of postoperative nausea and vomiting, small bowel intubation, radiological examination.
Christopher Leptak, MD., PhD.,
NDAs 17-854, 17-862, and 21-793. ANDAs 71-402, 72-744, 73-680, and 74-703
Tardive dyskinesia class-labeling for metoclopramide products

Product details for which this class-labeling applies

<table>
<thead>
<tr>
<th>Product</th>
<th>Manufacturer</th>
<th>Approval #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reglan tablets</td>
<td>Alaven Pharmaceuticals, LLC</td>
<td>NDA 17-854</td>
</tr>
<tr>
<td>(metoclopramide tablets, USP)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reglan injection</td>
<td>Baxter Healthcare Corporation</td>
<td>NDA 17-862</td>
</tr>
<tr>
<td>(metoclopramide injection, USP)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reglan ODT</td>
<td>Alaven Pharmaceuticals, LLC</td>
<td>NDA 21-793</td>
</tr>
<tr>
<td>(metoclopramide ODT, USP)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metoclopramide oral solution, USP</td>
<td>ANI Pharmaceuticals, Inc.</td>
<td>ANDA 71-402</td>
</tr>
<tr>
<td>Metoclopramide oral solution, USP</td>
<td>Pharmaceutical Associates, Inc.</td>
<td>ANDA 72-744</td>
</tr>
<tr>
<td>Metoclopramide oral solution, USP</td>
<td>Silax Pharmaceuticals, Inc.</td>
<td>ANDA 73-680</td>
</tr>
<tr>
<td>Metoclopramide oral solution, USP</td>
<td>Morton Grove Pharmaceuticals, Inc.</td>
<td>ANDA 74-703</td>
</tr>
</tbody>
</table>

Introduction and Reviewer’s Responsibilities:

The information, review, and recommendations provided within this document apply to all the products listed above. Exceptions and discussion unique to a specific product will be indicated. Additional information will include a summary of the comments and recommendations from the consultative disciplines.

Christopher Leptak reviewed the package inserts (PIs) for all the drug products.
Tamara Johnson reviewed the medication guides (MGs) for all the drug products.
The MG review immediately follows this document.

Background

Metoclopramide-containing products are currently marketed as prescription drugs in both oral and injection formulations. The original approval for this class of products was for an injectable formulation of metoclopramide hydrochloride (NDA 17-862, Baxter Healthcare Corporation) and was approved by the FDA on February 7, 1979. A metoclopramide oral solution (NDA 18-821, Robins AH) was approved by FDA on March 25, 1983 but was subsequently discontinued. This drug product for NDA 18-821 was the referenced innovator product to which subsequent generic equivalent drug products were compared.

Although metoclopramide-containing products have historically been shown to cause a spectrum of movement disorders, especially with prolonged use, a study undertaken by FDA OSE epidemiologists (Kaplan et al., “Duration of therapy with metoclopramide: a prescription claims data study.” Pharmacoepi Drug Safety, 2007, 16: 878-881) demonstrated that prolonged treatment with metoclopramide (longer than 90 days cumulative use) was common upon review of a claims data database.
Christopher Leptak, MD., PhD.,
NDAs 17-854, 17-862, and 21-793. ANDAs 71-402, 72-744, 73-680, and 74-703
Tardive dyskinesia class-labeling for metoclopramide products

In follow up, an OSE review dated June 27, 2008, evaluated the impact of prescribing patterns in which treatment duration extended beyond that recommended in the product labelings. That review concluded that metoclopramide use in chronic conditions such as GERD should be limited to patients for whom other safer treatment options have been exhausted, and initiated only after the patient has been informed of the risks and early warning signs of metoclopramide-induced movement disorders. To heighten awareness of the risks of developing movement disorders that can become irreversible, especially in the setting of increased duration of exposure or increased cumulative dose, the review recommended the addition a risk mitigation strategy including: 1) addition of a boxed warning, 2) an appropriate risk communication plan, including a medication guide and public health advisory, 3) consideration of convening an Advisory Committee, and 4) consideration of a long-term safety study to assess the risks associated with long-term metoclopramide use.

Based on this information and recommendations, companies with marketed metoclopramide-containing products were notified in December 2008 that their products had an identified safety issue that required the submission of a Risk Evaluation and Mitigation Strategy (REMS). To guide the companies, the notification included language recommendations regarding tardive dyskinesia (TD), the most common form of irreversible movement disorder associated with long-term metoclopramide use.

On 26 February, 2009, FDA sent a letter invoking its authority under section 505(o)(4) of the FDCA to require safety related label changes to address the risk of TD associated with the use of metoclopramide-containing products based on new safety information about this risk identified since the products were approved.

**Proposed Package Insert Language:**

1. Addition of Boxed Warning

```
WARNING: TARDIVE DYSKINESIA

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with duration of treatment and total cumulative dose.

Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.

Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

See WARNINGS
```
2. Addition of TD discussion to the Warnings Section of the label

WARNINGS:

Tardive Dyskinesia (see Boxed Warnings)

Treatment with metoclopramide can cause tardive dyskinesia (TD), a potentially irreversible and disfiguring disorder characterized by involuntary movements of the face, tongue, or extremities. Although the risk of TD with metoclopramide has not been extensively studied, one published study reported a TD prevalence of 20% among patients treated for at least 12 weeks. Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing TD.

Although the risk of developing TD in the general population may be increased among the elderly, women, and diabetics, it is not possible to predict which patients will develop metoclopramide-induced TD. Both the risk of developing TD and the likelihood that TD will become irreversible increase with duration of treatment and total cumulative dose.

Metoclopramide should be discontinued in patients who develop signs or symptoms of TD. There is no known effective treatment for established cases of TD, although in some patients, TD may remit, partially or completely, within several weeks to months after metoclopramide is withdrawn.

Metoclopramide itself may suppress, or partially suppress, the signs of TD, thereby masking the underlying disease process. The effect of this symptomatic suppression upon the long-term course of TD is unknown. Therefore, metoclopramide should not be used for the symptomatic control of TD.

Reviewer's Comment:

Based on review of the information FDA shared with the manufacturers of the metoclopramide-containing products, the review team made several modifications to the original proposal. These modifications were made after internal discussion between the review team and the internal consultants. After discussing the primary literature and the previous review team's recommendations, the new review team focused the TD discussion to highlight the main safety concern: extended duration of use and total cumulative dose beyond the label's recommendation. In addition, since the relevant literature studies could not readily differentiate sub-group risk factors associated with development of TD verses TD-associated with metoclopramide use, this
Christopher Leptak, MD, PhD.
NDAs 17-854, 17-862, and 21-793. ANDAs 71-402, 72-744, 73-680, and 74-703
Tardive dyskinesia class-labeling for metoclopramide products

information was removed from the boxed warning and discussed in greater detail in the Warning Section of the label.

Consults

1. Division of Drug Marketing, Advertising, and Communications (DDMAC) and Division of Risk Management (DRISK)
The consult’s review, comments, and recommendations were shared in the Memorandum dated 1 May, 2009. The comments were based on the proposed package inserts (PIs) by the companies. Of note, the comments were inclusive upon review of the entire proposed PI and thus included comments to sections that were not identified as areas of safety concern with respect to TD. Upon internal discussion, it was agreed upon that those recommendations pertinent to the identified safety issue would be addressed at this time. The main safety signal pertinent comments are summarized below with internal discussion and agreements italicized.

Package Insert (PI)

Boxed Warning
1. Clarification of the use of the term [removed text] to convey the important limitation to the indication. The term [removed text] was removed and replaced with a “12 week” defined time frame to better delineate the duration of metoclopramide use that represents increased risk of TD development.
2. Clarification of the age descriptive term “elderly” for the targeted patient population. The removal of a specific age lower limit was discussed previously and the proposal of [removed text] is best representative of the reported cases.

Warnings
1. [removed text]
2. [removed text]
Christopher Leptak, MD, PhD,
NDAs 17-854, 17-862, and 21-793. ANDAs 71-402, 72-744, 73-680, and 74-703
Tardive dyskinesia class-labeling for metoclopramide products

Recommendation

This reviewer agrees that the newly proposed labeling better reflects the risk factors associated with metoclopramide-induced TD based upon a review of the literature and following discussion with Dr. Pasricha, the lead author of the most recent published summary of the topic. The recommendation is to amend the labeling as proposed.

Of note, DDMAC and DRISK consult reviews contain information beyond the TD safety issue that should be considered should the labels for metoclopramide-containing products be converted to PLR format in the future.
Christopher Leptak, MD., PhD.,
NDAs 17-854, 17-862, and 21-793. ANDAs 71-402, 72-744, 73-680, and 74-703
Tardive dyskinesia class-labeling for metoclopramide-containing products

## CLINICAL REVIEW

<table>
<thead>
<tr>
<th>Application Type</th>
<th>Prior Approval Supplement</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Safety Labeling Changes under 505(o)(4)</td>
</tr>
<tr>
<td>Application Number(s)</td>
<td>NDA 17-854, 17-862, 21-793</td>
</tr>
<tr>
<td></td>
<td>ANDA 71-402, 72-744, 73-680, 74-703</td>
</tr>
<tr>
<td>Submit Date(s)</td>
<td>NDA 17-854 (051) March 25, 2009</td>
</tr>
<tr>
<td></td>
<td>NDA 17-862 (061) March 26, 2009</td>
</tr>
<tr>
<td></td>
<td>NDA 21-793 (004) March 25, 2009</td>
</tr>
<tr>
<td></td>
<td>ANDA 71-402 (S-007) March 27, 2009</td>
</tr>
<tr>
<td></td>
<td>ANDA 72-744 (S-010) March 31, 2009</td>
</tr>
<tr>
<td></td>
<td>ANDA 73-680 (S-017) March 17, 2009</td>
</tr>
<tr>
<td></td>
<td>ANDA 74-703 (S-006) March 27, 2009</td>
</tr>
<tr>
<td>Received Date(s)</td>
<td>NDA 17-854 (051) March 25, 2009</td>
</tr>
<tr>
<td></td>
<td>NDA 17-862 (061) March 27, 2009</td>
</tr>
<tr>
<td></td>
<td>NDA 21-793 (004) March 26, 2009</td>
</tr>
<tr>
<td></td>
<td>ANDA 71-402 (S-007) March 27, 2009</td>
</tr>
<tr>
<td></td>
<td>ANDA 72-744 (S-010) March 31, 2009</td>
</tr>
<tr>
<td></td>
<td>ANDA 73-680 (S-017) March 17, 2009</td>
</tr>
<tr>
<td></td>
<td>ANDA 74-703 (S-006) March 27, 2009</td>
</tr>
<tr>
<td>Amended PDUFA Goal Date</td>
<td>NDA 17-854 (051) June 24, 2009</td>
</tr>
<tr>
<td>(Original PDUFA date prior to two extensions to harmonize the timing of the class labeling submissions and product reviews: April 17, 2009)</td>
<td>NDA 21-793 (004) June 24, 2009</td>
</tr>
<tr>
<td></td>
<td>NDA 17-862/S-061 June 25, 2009</td>
</tr>
<tr>
<td></td>
<td>ANDA 71-402 (S-007) June 25, 2009</td>
</tr>
<tr>
<td></td>
<td>ANDA 72-744 (S-010) June 29, 2009</td>
</tr>
<tr>
<td></td>
<td>ANDA 73-680 (S-017) June 17, 2009</td>
</tr>
<tr>
<td></td>
<td>ANDA 74-703 (S-006) June 25, 2009</td>
</tr>
<tr>
<td>Reviewer Name(s)</td>
<td>Christopher Leptak, MD/PhD</td>
</tr>
<tr>
<td></td>
<td>Tamara Johnson, MD/MPH</td>
</tr>
<tr>
<td>Review Completion Date</td>
<td>May 22, 2009</td>
</tr>
<tr>
<td>Therapeutic Class</td>
<td>Motility modifier drugs (8015655)</td>
</tr>
<tr>
<td>Indication(s)¹</td>
<td>1. Relief of symptomatic gastroesophageal reflux</td>
</tr>
<tr>
<td></td>
<td>2. Diabetic gastroparesis</td>
</tr>
<tr>
<td>Intended Population(s)</td>
<td>1. Adult patients with symptomatic, documented GERD who fail to respond to conventional therapy.</td>
</tr>
<tr>
<td></td>
<td>2. Adult patients with acute or recurrent diabetic gastroparesis.</td>
</tr>
</tbody>
</table>

¹ Reglan injection (NDA 17-862) is not indicated for relief of symptomatic GERD. Additional indications for Reglan injection are prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, prevention of postoperative nausea and vomiting, small bowel intubation, radiological examination.
Christopher Leptak, MD., PhD.,
NDAs 17-854, 17-862, and 21-793. ANDAs 71-402, 72-744, 73-680, and 74-703
Tardive dyskinesia class-labeling for metoclopramide products

Product details for which this class-labeling applies

<table>
<thead>
<tr>
<th>Product</th>
<th>Manufacturer</th>
<th>Approval No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reglan tablets</td>
<td>Alaven Pharmaceuticals, LLC</td>
<td>NDA 17-854</td>
</tr>
<tr>
<td>(metoclopramide tablets, USP)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reglan injection</td>
<td>Baxter Healthcare Corporation</td>
<td>NDA 17-862</td>
</tr>
<tr>
<td>(metoclopramide injection, USP)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reglan ODT</td>
<td>Alaven Pharmaceuticals, LLC</td>
<td>NDA 21-793</td>
</tr>
<tr>
<td>(metoclopramide ODT, USP)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metoclopramide oral solution, USP</td>
<td>ANI Pharmaceuticals, Inc.</td>
<td>ANDA 71-402</td>
</tr>
<tr>
<td>Metoclopramide oral solution, USP</td>
<td>Pharmaceutical Associates, Inc.</td>
<td>ANDA 72-744</td>
</tr>
<tr>
<td>Metoclopramide oral solution, USP</td>
<td>Silax Pharmaceuticals, Inc.</td>
<td>ANDA 73-680</td>
</tr>
<tr>
<td>Metoclopramide oral solution, USP</td>
<td>Morton Grove Pharmaceuticals, Inc.</td>
<td>ANDA 74-703</td>
</tr>
</tbody>
</table>

Introduction and Reviewer's Responsibilities:

The information, review, and recommendations provided within this document apply to all the products listed above. Exceptions and discussion unique to a specific product will be indicated. Additional information will include a summary of the comments and recommendations from the consultative disciplines.

Christopher Leptak reviewed the package inserts (PIs) for all the drug products.
Tamara Johnson reviewed the medication guides (MGs) for all the drug products.

Background

Metoclopramide-containing products are currently marketed as prescription drugs in both oral and injection formulations. The original approval for this class of products was for an injectable formulation of metoclopramide hydrochloride (NDA 17-862, Baxter Healthcare Corporation) and was approved by the FDA on February 7, 1979. A metoclopramide oral solution (NDA 18-821, Robins AH) was approved by FDA on March 25, 1983 but was subsequently discontinued. This drug product for NDA 18-821 was the referenced innovator product to which subsequent generic equivalent drug products were compared.

Although metoclopramide-containing products have historically been shown to cause a spectrum of movement disorders, especially with prolonged use, a study undertaken by FDA OSE epidemiologists (Kaplan et al., “Duration of therapy with metoclopramide: a prescription claims data study.” Pharmacoepi Drug Safety, 2007, 16: 878-881) demonstrated that prolonged treatment with metoclopramide (longer than 90 days cumulative use) was common upon review of a claims data database.
Christopher Leptak, MD., PhD.,
NDAs 17-854, 17-862, and 21-793. ANDAs 71-402, 72-744, 73-680, and 74-703
Tardive dyskinesia class-labeling for metoclopramide products

In follow up, an OSE review dated June 27, 2008, evaluated the impact of prescribing patterns in which treatment duration extended beyond that recommended in the product labelings. That review concluded that metoclopramide use in chronic conditions such as GERD should be limited to patients for whom other safer treatment options have been exhausted, and initiated only after the patient has been informed of the risks and early warning signs of metoclopramide-induced movement disorders. To heighten awareness of the risks of developing movement disorders that can become irreversible, especially in the setting of increased duration of exposure or increased cumulative dose, the review recommended the addition a risk mitigation strategy including: 1) addition of a boxed warning, 2) an appropriate risk communication plan, including a medication guide and public health advisory, 3) consideration of convening an Advisory Committee, and 4) consideration of a long-term safety study to assess the risks associated with long-term metoclopramide use.

Based on this information and recommendations, companies with marketed metoclopramide-containing products were notified in December 2008 that their products had an identified safety issue that required the submission of a Risk Evaluation and Mitigation Strategy (REMS). To guide the companies, the notification included language recommendations regarding tardive dyskinesia (TD), the most common form of irreversible movement disorder associated with long-term metoclopramide use.

On 26 February, 2009, FDA sent a letter invoking its authority under section 505(o)(4) of the FDCA to require safety related label changes to address the risk of TD associated with the use of metoclopramide-containing products based on new safety information about this risk identified since the products were approved.

Proposed Package Insert Language:

1. Addition of Boxed Warning

<table>
<thead>
<tr>
<th>WARNING: TARDIVE DYKINESIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with duration of treatment and total cumulative dose.</td>
</tr>
<tr>
<td>Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.</td>
</tr>
<tr>
<td>Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.</td>
</tr>
<tr>
<td>See WARNINGS</td>
</tr>
</tbody>
</table>
Christopher Leptak, MD., PhD.,
NDAs 17-854, 17-862, and 21-793. ANDAs 71-402, 72-744, 73-680, and 74-703
Tardive dyskinesia class-labeling for metoclopramide products

2. Addition of TD discussion to the Warnings Section of the label

WARNINGS:

Tardive Dyskinesia (see Boxed Warnings)

Treatment with metoclopramide can cause tardive dyskinesia (TD), a potentially irreversible and disfiguring disorder characterized by involuntary movements of the face, tongue, or extremities. Although the risk of TD with metoclopramide has not been extensively studied, one published study reported a TD prevalence of 20% among patients treated for at least 12 weeks. Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing TD.

Although the risk of developing TD in the general population may be increased among the elderly, women, and diabetics, it is not possible to predict which patients will develop metoclopramide-induced TD. Both the risk of developing TD and the likelihood that TD will become irreversible increase with duration of treatment and total cumulative dose.

Metoclopramide should be discontinued in patients who develop signs or symptoms of TD. There is no known effective treatment for established cases of TD, although in some patients, TD may remit, partially or completely, within several weeks to months after metoclopramide is withdrawn.

Metoclopramide itself may suppress, or partially suppress, the signs of TD, thereby masking the underlying disease process. The effect of this symptomatic suppression upon the long-term course of TD is unknown. Therefore, metoclopramide should not be used for the symptomatic control of TD.

Reviewer’s Comment:

Based on review of the information FDA shared with the manufacturers of the metoclopramide-containing products, the review team made several modifications to the original proposal. These modifications were made after internal discussion between the review team and the internal consultants. After discussing the primary literature and the previous review team’s recommendations, the new review team focused the TD discussion to highlight the main safety concern: extended duration of use and total cumulative dose beyond the label’s recommendation. In addition, since the relevant literature studies could not readily differentiate sub-group risk factors associated with development of TD verses TD-associated with metoclopramide use, this
Christopher Leptak, MD., PhD.,
NDAs 17-854, 17-862, and 21-793. ANDAs 71-402, 72-744, 73-680, and 74-703
Tardive dyskinesia class-labeling for metoclopramide products

information was removed from the boxed warning and discussed in greater detail in the Warning Section of the label.

Consults

1. Division of Drug Marketing, Advertising, and Communications (DDMAC) and Division of Risk Management (DRISK)
The consult’s review, comments, and recommendations were shared in the Memorandum dated 1 May, 2009. The comments were based on the proposed package inserts (PIs) by the companies. Of note, the comments were inclusive upon review of the entire proposed PI and thus included comments to sections that were not identified as areas of safety concern with respect to TD. Upon internal discussion, it was agreed upon that those recommendations pertinent to the identified safety issue would be addressed at this time. The main safety signal pertinent comments are summarized below with internal discussion and agreements italicized.

Package Insert (PI)

Boxed Warning

1. Clarification of the use of the term [ ] to convey the important limitation to the indication. The term [ ] was removed and replaced with a “12 week defined time frame to better delineate the duration of metoclopramide use that represents increased risk of TD development.

Warnings

1. Clarification that consistent language be used for all the metoclopramide-containing products with regard to TD discussion of risk factors. The team agreed to make the appropriate changes.

Recommendation

This reviewer agrees that the newly proposed labeling better reflects the risk factors associated with metoclopramide-induced TD based upon a review of the literature and following discussion with Dr. Pasricha, the lead author of the most recent published summary of the topic. The recommendation is to amend the labeling as proposed.

Of note, DDMAC and DRISK consult reviews contain information beyond the TD safety issue that should be considered should the labels for metoclopramide-containing products be converted to PLR format in the future.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Christopher L Leptak
7/7/2009 02:45:54 PM
MEDICAL OFFICER
<table>
<thead>
<tr>
<th>Drug Product/Formulation/ Sponsor Name/ NDA or ANDA #</th>
<th>Indications:</th>
<th>Date of Submission</th>
<th>FDAAA Action Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reglan Tablets (Alaven Pharmaceuticals) NDA 017854</td>
<td>• Diabetic Gastroparesis (Diabetic Gastric Stasis)</td>
<td>March 25, 2009</td>
<td>June 24, 2009</td>
</tr>
<tr>
<td>Reglan Oral Disintegrating Tablets (Alaven Pharmaceuticals) NDA 021793</td>
<td>• Symptomatic Gastroesophageal Reflux Disease (GERD)</td>
<td>March 25, 2009</td>
<td>June 24, 2009</td>
</tr>
<tr>
<td>Metoclopramide oral solution (Morton Grove Pharmaceuticals) ANDA 074703</td>
<td></td>
<td>March 27, 2009</td>
<td>June 25, 2009</td>
</tr>
<tr>
<td>Metoclopramide oral solution (Silax Pharmaceuticals Inc) ANDA 073680</td>
<td></td>
<td>March 17, 2009</td>
<td>June 17, 2009</td>
</tr>
<tr>
<td>Metoclopramide oral solution (Pharmaceutical Associates Inc) ANDA 072744</td>
<td></td>
<td>March 31, 2009</td>
<td>June 29, 2009</td>
</tr>
<tr>
<td>Metoclopramide oral solution (ANI Pharmaceuticals Inc) ANDA 071402</td>
<td></td>
<td>March 27, 2009</td>
<td>June 25, 2009</td>
</tr>
<tr>
<td>Reglan Injection (Baxter Healthcare Corp) NDA 017862</td>
<td>• Diabetic gastroparesis (diabetic gastric stasis)</td>
<td>March 26, 2009</td>
<td>June 25, 2009</td>
</tr>
<tr>
<td></td>
<td>• Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Prevention of postoperative nausea and vomiting</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Small bowel intubation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Radiological examination</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Review completed: June 29, 2009
Reviewer: Tamara Johnson, MD, MS
Tamara Johnson, MD, MS
NDAs 17-854, 17-862, and 21-793. ANDAs 71-402, 72-744, 73-680, and 74-703
Tardive dyskinesia class-labeling for metoclopramide products

**Purpose**
As part of the Food and Drug Administration Amendments Act of 2007 (FDAAA) authorization, a class labeling and Risk Evaluation and Mitigation Strategy (REMS) safety initiative for metoclopramide products was initiated. The medication guides (MG) for the above listed products are reviewed in this document. The MGs for all current metoclopramide reference listed drugs (RLD) have been reviewed in accordance with the current product labeling (Package Inserts (PI)) and the recent FDA-proposed boxed warning and warning section language regarding the risk of tardive dyskinesia. As the original RLD for oral solutions has been withdrawn from marketing, the four currently marketed generic oral solutions were reviewed as RLDs. This document reflects the Division of Gastroenterology Products perspective on the MGs, and was completed subsequent to reviews performed by the Office of Safety Evaluation’s Division of Risk Management (DRISK) and the Division of Drug Marketing, Advertising, and Communications (DDMAC). The other REMS documents will be reviewed in an addendum document by Dr. Tamara Johnson, Division of Gastroenterology Products. The clinical review of the associated PIs was performed by Dr. Chris Leptak, Division of Gastroenterology Products. The PI review immediately precedes this document.

**Materials**
- Consultation Reviews completed by Sharon Mills of DRISK.
- Consultation Reviews completed by Shefali Doshi and Kathleen Klemm of DDMAC.

**Background**
The increasing concern regarding the risk of tardive dyskinesia with prolonged use of metoclopramide has prompted this safety initiative under FDAAA. The medical literature demonstrates that metoclopramide is now the leading cause of drug-induced movement disorders.\(^1\)\(^2\) Since the time of cisapride’s withdrawal from the US market in the year 2000, metoclopramide utilization has increased, especially in relation to the treatment of symptomatic GERD.\(^3\)\(^4\) Adverse event

Tamara Johnson, MD, MS
Tardive dyskinesia class-labeling for metoclopramide products

reports submitted to the FDA continue to link tardive dyskinesia to
metoclopramide use. The above described new safety information about the risk
of tardive dyskinesia authorizes FDA to require a REMS for approved drugs.

Medication Guide Review
The reviewed MGs include the language of the recent FDA-proposed boxed
warning and warnings sections, regarding the risk of tardive dyskinesia,
translated into a 6th–8th grade reading level, while other portions of the MGs are
harmonized across the class. Changes to MGs are detailed below.

I. The boxed warning and warnings sections are translated to all the MGs as:

What is the most important information I should know about
Metoclopramide?

Metoclopramide can cause serious side effects, including:

Abnormal muscle movements called tardive dyskinesia (TD). These
movements happen mostly in the face muscles. You can not control these
movements. They may not go away even after stopping Metoclopramide.
There is no treatment for TD, but symptoms may lessen or go away over time
after you stop taking Metoclopramide.

Your chances for getting TD go up:
• the longer you take Metoclopramide and the more Metoclopramide
  you take. You should not take Metoclopramide for more than 12
weeks.
• if you are older, especially if you are a woman
• if you have diabetes.

It is not possible for your doctor to know if you will get TD if you take
Metoclopramide.

Call your doctor right away if you get movements you can not stop or control,
such as:
• lip smacking, chewing, or puckering up your mouth
• frowning or scowling
• sticking out your tongue
• blinking and moving your eyes
• shaking of your arms and legs

See the section “What are the possible side effects of Metoclopramide?”

• Note: For Reglan tradename products, Reglan is substituted for Metoclopramide in
the above text.

4 Shaffer D, Butterfield M, Pamer C, Corken Mackey A. Tardive dyskinesia risks and metoclopramide use
Tamara Johnson, MD, MS  
NDAs 17-854, 17-862, and 21-793. ANDAs 71-402, 72-744, 73-680, and 74-703  
Tardive dyskinesia class-labeling for metoclopramide products

II. In the first paragraph, introductory language was added to emphasize to the patient that each specific metoclopramide product has its own particular medication guide: “If you take another product that contains metoclopramide (such as REGLAN tablets, REGLAN ODT, REGLAN injection, or metoclopramide oral syrup), you should read the Medication Guide that comes with that product. Some of the information may be different.” These two statements especially make REGLAN injection patients aware of the other forms of metoclopramide.

III. Under “What are the possible side effects of Metoclopramide” – serious side effects, the description of uncontrolled spasms (dystonia) was relocated to a position after that for abnormal muscle movements (tardive dyskinesia) and before that for depression. This re-ordering is believed to better demonstrate decreasing frequency of the serious side effects.

IV. Under the serious side effects section, a statement regarding the risk population for dystonia is added to better reflect the PI. It reads as: “These spasms happen more often in children and adults under age 30.” DRISK and DDMAC had similar recommendations and agreed with the final wording.

V. Under the serious side effects section, an additional statement regarding pre-existing Parkinson's disease and metoclopramide use was added to all MGs to better describe the risk: “If you already have Parkinson’s disease, your symptoms may become worse while you are receiving REGLAN ODT.”

VI. The common side effects profile listed in the MG is not expanded and, remains unchanged – consistent with that found in the Reglan tablets PI. This is because the adverse reaction listing in the PI does not provide estimates of frequency for each listed event. The listed CNS effects are cited in both the PI and in recent medical literature to occur in up to 10% of patients. All other adverse reactions occur much less frequently (<2%).

VII. In the “What should I avoid while taking metoclopramide?” section, a second sentence was added to clarify the guidance on dangerous tasks. The bullet therefore reads as follows: “Do not drive, work with machines, or do dangerous tasks until you know how Metoclopramide affects you. **Metoclopramide may cause sleepiness.**

---

As each product's MG was compared to that for REGLAN tablets and harmonized by DRISK, further comments are noted if a change from the DRISK revised MGs was advocated by this reviewer or the change gained general consensus amongst the safety review team. DDMAC recommendations were mostly incorporated in the DRISK revised MGs, however, a few recommendations are visited below.

VIII. Changes specific to all metoclopramide oral solution ANDA products include:

1) The phonetic spelling of metoclopramide is now consistent across the oral solutions as "met-o-KLO-pra-mide".

IX. Changes specific to Reglan Injection (Baxter) NDA 17-862

1) The beginning of the introductory paragraph was kept as "You or your caregiver should read the Medication Guide . . . ", to address the different circumstances in which Reglan injection is administered when compared to the oral products, such as hospital, infusion center or in-home nursing care.

2) Comment: Aside from language specific to Reglan injection, the MG differed slightly from that of Reglan tablets because portions of the Reglan Injection PI needs to be updated to include missing content on 1) withdrawal symptoms and 2) the diabetic gastroparesis indication regarding symptoms relieved with metoclopramide use. Since all Reglan products were initially under one PI until sold to new sponsors, the PIs for these three products should have mostly similar language and content.

X. From the DDMAC review of the metoclopramide products, the comments that were not resolved through changes from the DRISK review were considered as follows:

1) The recommendation to further elaborate on endocrine disorders, GI upset, and hypo-/hypertension. Further explanation may not be as helpful for the general patient population in the MG. Endocrine disturbances do occur but mostly with long-term use – the circumstance we are currently taking action to avoid. GI upset is nonspecific and depending on the formulation may be more nausea/vomiting or diarrhea. (Diarrhea is expected with increased GI motility.) Lastly, the change in blood pressure is specific to patients with certain conditions which are addressed elsewhere in the MG.

2) The comment about the accuracy of the statement, "Rarely, men have had production of breast milk." This is true as the endocrine disorders are prolactin-based changes, breast milk production is
Tamara Johnson, MD, MS
NDAs 17-854, 17-862, and 21-793. ANDAs 71-402, 72-744, 73-680, and 74-703
Tardive dyskinesia class-labeling for metoclopramide products

stimulated. But these side effects would not occur with short-term use.

3) **Diabetes is an independent risk factor for Tardive Dyskinesia.** This was demonstrated in the psychiatry literature with antipsychotic agents that share the same mechanism of action as metoclopramide, and has been understood in gastroenterology clinical practice.\(^7\) Ganzini et al. have also demonstrated some association of diabetes on development of tardive dyskinesia in patients.\(^8\)

4) **For the comment regarding including breast cancer on the list of conditions to tell your doctor.** There is toxicological data that the use of metoclopramide or other dopamine receptor antagonists may aggravate breast cancer development. This is believed to be due to the increased prolactin levels. The information is not definitive in humans, but 1/3 of human breast cancers are prolactin-dependent. This information is written in the Toxicology and Mutagenesis section of the PI for metoclopramide products.

---


This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
Christopher L Leptak
6/30/2009 07:15:13 AM
MEDICAL OFFICER

Tamara N Johnson
6/30/2009 08:51:19 AM
MEDICAL OFFICER

Nancy Snow
6/30/2009 09:02:29 AM
MEDICAL OFFICER
APPLICATION NUMBER:
ANDA 74-703/S-006

OTHER REVIEWS
Date: April 24, 2009
To: Gary Buehler, Division Director
Office of Generic Drugs (OGD)
Donna Griebel, M.D., Division Director
Division of Gastroenterology Drug Products (DGP)
Through: Jodi Duckhorn, M.A., Team Leader
Division of Risk Management (DRISK)
From: Sharon R. Mills, BSN, RN, CCRP
Patient Product Information Reviewer
Division of Risk Management (DRISK)
Subject: DRISK Review of Patient Labeling (Medication Guide)
Drug Name(s): Metoclopramide Oral Solution, USP
Application Type/Number: ANDA 74-703
Submission Number: S-006
Applicant/sponsor: Morton Grove Pharmaceuticals, Inc.
OSE RCM #: 2009-604
1 INTRODUCTION

This review is written in response to a request from the Division of Gastroenterology Drug Products (DGP) and Office of Generic Drugs (OGD) for the Division of Risk Management to review the Applicant’s proposed Medication Guide for Metoclopramide Oral Solution, USP.

FDA has determined that Metoclopramide Oral Syrup, USP poses a serious and significant public health concern requiring the distribution of a Medication Guide. The Medication Guide is necessary for patients’ safe and effective use of Metoclopramide Oral Syrup, USP. FDA has determined that Metoclopramide Oral Syrup, USP is a product with a serious a significant public health concern that meets two of the three criteria for a Medication Guide as set forth in 21 CFR 208.1: Metoclopramide Oral Syrup, USP is a product that has serious risks (relative to benefits) of which patients should be made aware because information concerning the risks could affect patients’ decision to use or continue to use; Metoclopramide Oral Syrup, USP is a product for which patient labeling could help prevent serious adverse events.

2 MATERIAL REVIEWED


3 BACKGROUND

Morton Grove Pharmaceuticals, Inc. Abbreviated New Drug Application, ANDA 74-703, for Metoclopramide Oral Solution, USP, was approved on October 31, 1997.

Metoclopramide Oral Solution is indicated for:

- **Symptomatic Gastroesophageal Reflux:**
  Reglan tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy.
- **Diabetic Gastroparesis (Diabetic Gastric Stasis):**
  Reglan tablets are indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis.

OGD informed the Applicant that a Risk Evaluation and Mitigation Strategy (REMS) is necessary for Metoclopramide Oral Solution in a Prior Approval Supplement Request letter dated February 26, 2009, due to the serious risk of Tardive Dyskinesia (TD). The only elements of the REMS will be a Medication Guide and a timetable of submission of assessments of the REMS.

The Applicant submitted a proposed REMS for Metoclopramide Oral Solution on March 26, 2009. The REMs is currently under review by DRISK, and will be provided to OGD and DGP under separate cover.
4 DISCUSSION

The purpose of patient directed labeling is to facilitate and enhance appropriate use and provide important risk information about medications. Our recommended changes are consistent with current research to improve risk communication to a broad audience, including those with lower literacy.

The draft MG submitted by the Applicant has a Flesch Kinkaid grade level of 8.4, and a Flesch Reading Ease score of 52.3%. To enhance patient comprehension, materials should be written at a 6th to 8th grade reading level, and have a reading ease score of at least 60% (60% corresponds to an 8th grade reading level). Our revised MG has a Flesch Kinkaid grade level of 7.6 and a Flesch Reading Ease score of 59.8%.

In our review of the MG, we have:
• simplified wording and clarified concepts where possible,
• ensured that the MG is consistent with the PI,
• removed unnecessary or redundant information
• ensured that the MG meets the Regulations as specified in 21 CFR 208.20.
• ensured that the MG meets the criteria as specified in FDA’s Guidance for Useful Written Consumer Medication Information (published July 2006).

In 2008, The American Society of Consultant Pharmacists Foundation in collaboration with The American Foundation for the Blind published Guidelines for Prescription Labeling and Consumer Medication Information for People with Vision Loss. They recommend using fonts such as Arial, Verdana, or APHont to make medical information more accessible for patients with low vision. We have reformatted the MG document using the font APHont, which was developed by the American Printing House for the Blind specifically for low vision readers.

See the attached document for our recommended revisions to the MG. Comments to the review division are *bolded, underlined and italicized*.

We are providing the review division a marked-up and clean copy of the revised MG. We recommend using the clean copy as the working document. All future relevant changes to the PI should also be reflected in the MG.

5 CONCLUSIONS AND RECOMMENDATIONS

We have the following comments on the proposed Medication Guide:

1. The review division should ensure consistency among all of the MGs for the Metoclopramide ANDA products for phonetic spelling, as well as referencing the product as “Metoclopramide” and use of either lower case or upper case for spelling Metoclopramide. For brevity, we recommend using “Metoclopramide” rather than “Metoclopramide Oral Solution” throughout the MGs.

2. We have made the information in the section “What is Metoclopramide?” consistent with the labeled indication and with the other MGs for products in this class. We have added a pediatric statement at the end of this section.

3. In the section “What are the possible side effects of Metoclopramide?”
   • We made this section of the MG consistent across all MGs in the class.
• The applicant should clarify how they chose the common side effects proposed in the MG. The review division should clarify whether side effects from any other body system are relevant to include in the MG, particularly allergic reactions since no percentages are given except for CNS side effects. We have made the list of common side effects more patient-friendly and consistent with the list in the Reglan Tablets and Reglan ODT MGs.

• The applicant included information about (b)(4) We deleted this information because it is not included in the MGs for other products in the class. The review division should determine if it is appropriate to include this type of information in the MG. If so, language should be added to this section of all MGs for products in the class.

Please let us know if you have any questions.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Sharon Mills
4/24/2009 02:52:50 PM
DRUG SAFETY OFFICE REVIEWER

Jodi Duckhorn
4/24/2009 03:16:48 PM
DRUG SAFETY OFFICE REVIEWER
APPLICATION NUMBER:
ANDA 74-703/S-006

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS
ANDA 74-703

Morton Grove Pharmaceuticals, Inc.
Attention: Ralph Hodosh
50 Lakeview Parkway, Suite 127
Vernon Hills, IL 60061

Dear Sir:

Please refer to your Abbreviated New Drug Application ANDA 74-703 for Metoclopramide Oral Solution USP, 5 mg/5 mL, which was approved on October 31, 1997.

Title IX, Subtitle A, Section 901 of the Food and Drug Administration Amendments Act of 2007 (FDAAA) amends the Federal Food, Drug, and Cosmetic Act (FDCA) to provide FDA with new authorities to require holders of approved drugs to develop and comply with Risk Evaluation and Mitigation Strategies (REMS) (section 505-1 of the FDCA) and to make safety related labeling changes (section 505(o)(4) of the FDCA) based upon new safety information that becomes available after approval of the drug. This provision took effect on March 25, 2008.

Section 505(o)(4) also authorizes FDA to require the holder of an approved application under section 505(j) (an abbreviated new drug application or ANDA) to make safety related label changes based upon new safety information if the same drug approved under section 505(b) is not currently marketed. You are the holder of ANDA 74-703 which references a drug approved under section 505(b) that is withdrawn and not currently marketed.

Your ANDA for Metoclopramide Oral Solution USP, 5 mg/5 mL was approved on October 31, 1997. Current product labeling warns of the risk of tardive dyskinesia, a serious movement disorder, with chronic metoclopramide treatment. Tardive dyskinesia is often irreversible. Several risk factors, including female gender, advanced age, treatment duration and total cumulative dose have been described. Recently published analyses suggest that metoclopramide has surpassed haloperidol as the most common cause of drug-induced movement disorders.1,2 A published FDA analysis of metoclopramide utilization patterns showed that prescription claims for cumulative periods longer than 90 days were recorded for a substantial

portion of patients in that study.\textsuperscript{3} In addition, we have become aware of continued spontaneous reports to the FDA of tardive dyskinesia associated with metoclopramide use. Exposure greater than 12 weeks was evident in a majority of these reports. This information was not available when your ANDA was approved. We consider this information to be “new safety information” as defined in FDAAA.

After consideration of the new safety information described above, we believe that safety related changes should be included in the labeling for Metoclopramide Oral Solution USP, 5 mg/5 mL. We have also determined that a REMS for each drug is necessary to ensure that the benefits of the drugs outweigh the risks. These requirements are described further below.

### SAFETY LABELING CHANGES

In accordance with section 505(o)(4) of the FDCA, we are notifying you that based on the new safety information described above, we believe that the new safety information should be included in the labeling for Metoclopramide Oral Solution USP, 5 mg/5 mL as follows (additions are noted by underline and deletions are noted by strikethrough):

- The addition of a **Boxed Warning** to alert physicians of the risk of tardive dyskinesia with chronic use of metoclopramide, to include the following language:

  **WARNING: TARDIVE DYSKINESIA**

  Chronic treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose. The elderly, especially elderly women, are most likely to develop this condition.

  Metoclopramide therapy should routinely be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia; however, in some patients symptoms may lessen or resolve after metoclopramide treatment is stopped.

  Prolonged treatment (greater than 12 weeks) with metoclopramide should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risks to the patient of developing tardive dyskinesia. See **WARNINGS**

- Revisions to the **Warnings** section of the label to include the following language as the first subsection:

  **Tardive Dyskinesia**

  Tardive dyskinesia, a syndrome consisting of potentially irreversible, involuntary, dyskinetic

movements may develop in patients treated with metoclopramide. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to predict which patients are likely to develop the syndrome. Both the risk of developing the syndrome and the likelihood that it will become irreversible are believed to increase with the duration of treatment and the total cumulative dose.

Less commonly, the syndrome can develop after relatively brief treatment periods at low doses; in these cases, symptoms appear more likely to be reversible.

There is no known treatment for established cases of tardive dyskinesia although the syndrome may remit, partially or completely, within several weeks to months after metoclopramide is withdrawn. Metoclopramide itself, however, may suppress (or partially suppress) the signs of tardive dyskinesia, thereby masking the underlying disease process. The effect of this symptomatic suppression upon the long-term course of the syndrome is unknown. Therefore, the use of metoclopramide for the symptomatic control of tardive dyskinesia is not recommended.

**Tardive dyskinesia**

Tardive dyskinesia (TD), a potentially irreversible and disfiguring disorder characterized by involuntary movements of the face, tongue, or extremities, can develop in patients treated with metoclopramide. Although the risk of tardive dyskinesia (TD) with metoclopramide has not been extensively studied, one published study reported a TD prevalence of 20% among patients treated for at least 3 months.

The prevalence of the syndrome appears to be highest among the elderly, especially elderly women. It is impossible to predict which patients are likely to develop the syndrome. Both the risk of developing the syndrome and the likelihood that it will become irreversible are believed to increase with the duration of treatment and the total cumulative dose.

There is no known effective treatment for established cases of tardive dyskinesia although the syndrome may remit, partially or completely, within several weeks to months after metoclopramide is withdrawn. Metoclopramide itself, however, may suppress (or partially suppress) the signs of tardive dyskinesia, thereby masking the underlying disease process. The effect of this symptomatic suppression upon the long-term course of the syndrome is unknown. Therefore, metoclopramide should not be used for the symptomatic control of tardive dyskinesia.

- The addition of a **Medication Guide**

In addition to the changes described above to the labeling, you should submit a proposed Medication Guide for Metoclopramide Oral Solution USP, 5 mg/5 mL. Your Medication Guide must include information about the serious risk of tardive dyskinesia and will be considered part of the proposed REMS.

In accordance with section 505(o)(4), within 30 days of the date of this letter, you must submit a prior approval supplement proposing changes to the approved labeling for Metoclopramide Oral Solution USP, 5 mg/5 mL in accordance with the above direction, or
notify FDA that you do not believe a labeling change in warranted, and submit a statement
detailing the reasons why such a change is not warranted.

Include labeling in both Microsoft Word format and final printed labeling in PDF format.
To facilitate review of your submission, provide a highlighted or marked-up copy that shows
the changes that are being made.

Use the following designators to prominently label all submissions, including supplements,
relating to this safety label change as appropriate:

**Safety Labeling Changes under 505(o)(4)**

**RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS**

In accordance with section 505-1(a) of the FDCA, we have determined that a REMS is necessary
for Metoclopramide Oral Solution USP, 5 mg/5 mL to ensure that the benefits of the drugs
outweigh the risks based on the new safety information described above.

Your proposed REMS must include the following:

**Medication Guide:** As one element of a REMS, FDA may require the development of a
Medication Guide as provided for under 21 CFR Part 208. The approved Medication Guide
submitted as a safety labeling change, noted above, will be considered part of the REMS in
accordance with 505-1(a). Pursuant to 21 CFR Part 208 and 505-1(e)(2), FDA has determined
that Metoclopramide Oral Solution USP, 5 mg/5 mL poses a serious and significant public health
concern requiring the distribution of a Medication Guide. The Medication Guide is necessary for
patients’ safe use of Metoclopramide Oral Solution USP, 5 mg/5 mL. FDA has determined that
Metoclopramide Oral Solution USP, 5 mg/5 mL has serious risks (relative to benefits) of which
patients should be made aware because information concerning the risks could affect patients’
decisions to use, or continue to use Metoclopramide Oral Solution USP, 5 mg/5 mL. FDA has
determined that Metoclopramide Oral Solution USP, 5 mg/5 mL is a product for which patient
labeling could help prevent serious adverse events. Under 21 CFR 208 and in accordance with
505-1, you are responsible for ensuring that the Medication Guide is available for distribution to
patients who are dispensed Metoclopramide Oral Solution USP, 5 mg/5 mL.

In accordance with section 505-1, within 30 days of the date of this letter, you must submit a
proposed REMS. The REMS, once approved, will create enforceable obligations.

We suggest that your proposed REMS submission include two parts: a “Proposed REMS” and a
“REMS Supporting Document.” Attached is a template for the Proposed REMS that you should
complete with concise, specific information (see Appendix A). Include information in the
template that is specific to your proposed REMS for Metoclopramide Oral Solution USP, 5 mg/5
mL. Once FDA finds the content acceptable, we will include this document as an attachment to
the approval letter that includes the REMS.

The REMS Supporting Document should be a document explaining the rationale for each of the
elements included in the proposed REMS (see Appendix B).
If you do not submit electronically, please send 5 copies of your proposed REMS and REMS Supporting Document as an amendment to your ANDA. Prominently identify the amendment containing the proposed REMS with the following wording in bold capital letters at the top of the first page of the submission:

NEW SUPPLEMENT FOR ANDA 74-703
PROPOSED REMS

On the first page of subsequent submissions related to your proposed REMS, prominently identify the submission by including this wording in bold, capital letters at the top of the page:

SUPPLEMENT <<insert assigned #>>
PROPOSED REMS-AMENDMENT

If you have any questions, call Sarah Park, Labeling Reviewer, at 240-276-8995.

Sincerely,

{See appended electronic signature page}

Gary Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research

Enclosure: REMS Template
Appendix A- REMS Template

If you are not proposing to include one of the listed elements, include a statement that the element is not necessary.

Application number TRADE NAME (DRUG NAME)

Class of Product as per label

Applicant name
   Address
   Contact Information

PROPOSED RISK EVALUATION AND MITIGATION STRATEGY (REMS)

I. GOAL(S):

List the goals and objectives of the REMS.

II. REMS ELEMENTS:

   A. Medication Guide or PPI

   If a Medication Guide is included in the proposed REMS, include the following:

   A Medication Guide will be dispensed with each [drug name] prescription. [Describe in detail how you will comply with 21 CFR 208.24.]

   B. Communication Plan

   If a Communication Plan is included in the proposed REMS, include the following:

   [Applicant] will implement a communication plan to healthcare providers to support implementation of this REMS.

   List elements of communication plan. Append the printed material and web shots to the REMS Document

   C. Elements To Assure Safe Use

   If one or more Elements to Ensure Safe Use are included in the proposed REMS, include the following:
List elements to assure safe use included in this REMS. Elements to assure safe use may, to mitigate a specific serious risk listed in the labeling, require that:

A. Healthcare providers who prescribe [drug name] have particular training or experience, or are specially certified. Append any enrollment forms and relevant attestations/certifications to the REMS;

B. Pharmacies, practitioners, or healthcare settings that dispense [drug name] are specially certified. Append any enrollment forms and relevant attestations/certifications to the REMS;

C. [Drug name] may be dispensed to patients only in certain healthcare settings (e.g., hospitals);

D. [Drug name] may be dispensed to patients with documentation of safe-use conditions;

E. Each patient using [drug name] is subject to certain monitoring. Append specified procedures to the REMS; or

F. Each patient using [drug name] be enrolled in a registry. Append any enrollment forms and other related materials to the REMS Document.

D. Implementation System

If an Implementation System is included in the proposed REMS, include the following:

Describe the implementation system to monitor and evaluate implementation for, and work to improve implementation of, Elements to Assure Safe Use (B), (C), and (D), listed above.

E. Timetable for Submission of Assessments

If a Timetable for Submission of Assessments is included in the proposed REMS, include the following:

Specify the timetable for submission of assessments of the REMS. The timetable for submission of assessments at a minimum must include an assessment by 18 months, 3 years, and in the 7th year after the REMS is initially approved, with dates for additional assessments if more frequent assessments are necessary to ensure that the benefits of the drug continue to outweigh the risks.
Appendix B - REMS Supporting Document Template

This REMS Supporting Document should include the following listed sections 1 through 5, as well as a table of contents. If you are not proposing to include one of the listed elements, the REMS Supporting Document should simply state that the element is not necessary. Include in section 3 the reason you believe each of the potential elements you are proposing to include in the REMS is necessary to ensure that the benefits of the drug outweigh the risks.

1. Background

2. Goals

3. Supporting Information on Proposed REMS Elements
   a. Additional Potential Elements
      i. Medication Guide
      ii. Patient Package Insert
      iii. Communication Plan
   b. Elements to Assure Safe Use, including a statement of how the elements to assure safe use will mitigate the observed safety risk
   c. Implementation System
   d. Timetable for Assessment of the REMS

4. Information Needed for Assessments

5. Other Relevant Information
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------
Robert L. West
2/26/2009 01:04:14 PM
Deputy Director, for Gary Buehler
26 March 2009

Gary J. Buehler, Director
Office of Generic Drugs, CDER
Food and Drug Administration
Metro Park North 4 (MPN 4), HFD-600
7519 Standish Place
Rockville, Maryland 20855

Re: Prior Approval Supplement for ANDA 74-703 Metoclopramide Oral Solution
USP, 5 mg/5 mL; Safety Label Changes under FDCA 505 (o)(4) and Proposed
REMS

Dear Mr. Buehler:

As the authorized regulatory agent for Wockhardt EU Operations (Swiss) A.G.
(“Wockhardt EU”), Morton Grove Pharmaceuticals, Inc. (“MGP”) hereby submits this
supplement to ANDA 74-703. This supplement is submitted in response to the FDA
letter sent to MGP via facsimile on 26 February 2009 in which the FDA requested:

- Safety related label changes under FDCA section 505 (o)(4), and
- A proposed Risk Evaluation and Mitigation Strategy (REMS), with medication
guide and REMS Supporting Document, under FDCA section 505-1.

This submission is being made in duplicate. With each copy, I have enclosed a CD-ROM
containing revised labeling, medication guide, REMS, and REMS supporting document.
Each CD-ROM was prepared in accordance with FDA’s guidance Providing Regulatory
Submissions in Electronic Format – ANDAs dated June 2002. The enclosed CD-ROMs
were scanned with Symantec/Norton anti-viral software, and they are virus free.

Please contact me for additional information required to process this supplement.

Sincerely,

Ralph J. Hodosh, PhD
Director, Regulatory Affairs
Tele: 847.410.6708 (New Number)
Email: rhodosh@mgp-online.com
REQUEST FOR CONSULTATION

TO (Office/Division): Nina Ton, Pharm.D. Safety Regulatory Manager
OSE

FROM (Name, Office/Division, and Phone Number of Requestor):
Kristen Everett, Safety Regulatory Manager, DGP

DATE
April 3, 2009

IND NO.

NDA NO.
multiple- see below

TYPE OF DOCUMENT

DATE OF DOCUMENT
March 17, 2009 (earliest submission)

NAME OF DRUG
metoclopramide class

PRIORITY CONSIDERATION
FDAAA

CLASSIFICATION OF DRUG
motility modifiers

DESIRE COMPLETION DATE
May 1, 2009

NAME OF FIRM: Alaven Pharm., ANI, Silarx, Morton Grove, Pharmaceutical Associates

REASON FOR REQUEST

I. GENERAL

☐ NEW PROTOCOL
☐ PROGRESS REPORT
☐ NEW CORRESPONDENCE
☐ DRUG ADVERTISING
☐ ADVERSE REACTION REPORT
☐ MANUFACTURING CHANGE / ADDITION
☐ MEETING PLANNED BY
☐ PRE-NDA MEETING
☐ END-OF-PHASE 2a MEETING
☐ END-OF-PHASE 2 MEETING
☐ RESUBMISSION
☐ SAFETY / EFFICACY
☐ PAPER NDA
☐ CONTROL SUPPLEMENT
☐ RESPONSE TO DEFICIENCY LETTER
☐ FINAL PRINTED LABELING
☐ LABELING REVISION
☐ ORIGINAL NEW CORRESPONDENCE
☐ FORMULATIVE REVIEW
☐ OTHER (SPECIFY BELOW):

II. BIOMETRICS

☐ PRIORITY P NDA REVIEW
☐ END-OF-PHASE 2 MEETING
☐ CONTROLLED STUDIES
☐ PROTOCOL REVIEW
☐ OTHER (SPECIFY BELOW):
☐ CHEMISTRY REVIEW
☐ PHARMACOLOGY
☐ BIOPHARMACEUTICS
☐ OTHER (SPECIFY BELOW):

III. BIOPHARMACEUTICS

☐ DISSOLUTION
☐ BIOAVAILABILITY STUDIES
☐ PHASE 4 STUDIES
☐ DEFICIENCY LETTER RESPONSE
☐ PROTOCOL - BIOPHARMACEUTICS
☐ IN-VIVO WAIVER REQUEST

IV. DRUG SAFETY

☐ PHASE 4 SURVEILLANCE/EPIEDEMOLOGY PROTOCOL
☐ DRUG USE, e.g. POPULATION EXPOSURE, ASSOCIATED DIAGNOSES
☐ CASE REPORTS OF SPECIFIC REACTIONS (List below)
☐ COMPARATIVE RISK ASSESSMENT ON GENERIC DRUG GROUP
☐ REVIEW OF MARKETING EXPERIENCE, DRUG USE AND SAFETY
☐ SUMMARY OF ADVERSE EXPERIENCE
☐ POISON RISK ANALYSIS

V. SCIENTIFIC INVESTIGATIONS

☐ CLINICAL
☐ NONCLINICAL

COMMENTS / SPECIAL INSTRUCTIONS: DGP and OGD request your expertise in the review of the medication guides and REMS documents submitted for the products listed below. EDR links, where available, are provided for the submissions. In addition, package inserts, MGs, and REMS documents will be available in the GI eRoom (Safety folder, REMS/FDAAA Safety Labeling under review, metoclopramide subfolder). The class language that needs to be harmonized across the medication guides is the Boxed warning, and the Tardive Dyskinesia subsection under Warnings (this language is also provided in the supplement request letter sent to the sponsors). The REMS documents should also be fairly similar in that the REMS goal should be the same; however, sponsors may have different methods of distributing the medication guide.

ANDA 71-402ANI (oral syrup) submitted: 3/26/09 - insert, med guide, REMS (missing container label)
\CDSESUB1\EVSPROD\ANDA071402\0001

ANDA 74-703Morton Grove (oral syrup) submitted: 3/26/09 - insert, med guide, REMS, container label
\FDSWA150\NONECTD\N74703\S_006\2009-03-26
| ANDA 73-680 Silarx (oral syrup) submitted: 3/17/09 - insert, med guide, REMS (missing container label) |
| \CDSESUB1\EVSPROD\ANDA073680\0002 |
| ANDA 72-744 Pharmaceutical Associates (oral syrup) submitted: 3/30/09 - med guide and REMS (missing insert and container label) - Not sure if this is electronic. OGD is waiting for their document room to check. |
| NDA 17-854 Alaven (Reglan Tablets) submitted 3-25-09 |
| Med Guide submission: S-051 |
| The network location is: \FDSWA150\NONECTD\N17854\S_051\2009-03-25 |
| REMS Submission: S-052 |
| The network location is: \FDSWA150\NONECTD\N17854\S_052\2009-03-25 |
| NDA 21-793, Alaven (Reglan ODT) submitted 3-25-09 |
| Med Guide submission: S-004 |
| The network location is: \FDSWA150\NONECTD\N21793\S_004\2009-03-25 |
| REMS Submission: S-005 |
| The network location is: \FDSWA150\NONECTD\N21793\S_005\2009-03-25 |

| SIGNATURE OF REQUESTOR |
| Kristen Everett/Joyce Korvick |

| METHOD OF DELIVERY (Check one) |
| DFS | EMAIL | MAIL | HAND |

| PRINTED NAME AND SIGNATURE OF RECEIVER |
| PRINTED NAME AND SIGNATURE OF DELIVERER |
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------
Kristen Everett
4/3/2009 02:27:52 PM
# REQUEST FOR CONSULTATION

**TO:** Wayne Amchin, DDMAC  
**FROM:** Kristen Everett, SRPM, DGP  

**DATE:** April 6, 2009  
**IND NO.:** multiple—see below  
**NDA NO.:** multiple—see below  
**TYPE OF DOCUMENT:** REMS - MG  
**DATE OF DOCUMENT:** March 17, 2009 (earliest submission)  

**NAME OF DRUG:** Metoclopramide class  
**PRIORITY CONSIDERATION:**  
**CLASSIFICATION OF DRUG:** Motility modifiers  
**DESERED COMPLETION DATE:** May 1, 2009  

**NAME OF FIRM:** Alaven Pharma, ANI, Silax, Morton Grove, Pharmaceutical Associates

## REASON FOR REQUEST

### I. GENERAL

- NEW PROTOCOL
- PROGRESS REPORT
- NEW CORRESPONDENCE
- DRUG ADVERTISING
- ADVERSE REACTION REPORT
- MANUFACTURING CHANGE / ADDITION
- MEETING PLANNED BY
  - PRE-NDA MEETING
  - END-OF-PHASE 2a MEETING
  - END-OF-PHASE 2 MEETING
  - RESUBMISSION
  - SAFETY / EFFICACY
  - PAPER NDA
  - CONTROL SUPPLEMENT
- RESPONSE TO DEFICIENCY LETTER
- FINAL PRINTED LABELING
- LABELING REVISION
- ORIGINAL NEW CORRESPONDENCE
- FORMULATIVE REVIEW
- OTHER (SPECIFY BELOW):  

### II. BIOMETRICS

- PRIORITY P NDA REVIEW
- END-OF-PHASE 2 MEETING
- CONTROLLED STUDIES
- PROTOCOL REVIEW
- OTHER (SPECIFY BELOW):  

### III. BIOPHARMAECUTICS

- DISSOLUTION
- BIOAVAILABILITY STUDIES
- PHASE 4 STUDIES
- CHEMISTRY REVIEW
- PHARMACOLOGY
- BIOPHARMAECUTICS
- OTHER (SPECIFY BELOW):  

### IV. DRUG SAFETY

- PHASE 4 SURVEILLANCE/EPIEMIOLOGY PROTOCOL
- DRUG USE, e.g., POPULATION EXPOSURE, ASSOCIATED DIAGNOSES
- CASE REPORTS OF SPECIFIC REACTIONS (List below)
- COMPARATIVE RISK ASSESSMENT ON GENERIC DRUG GROUP
- REVIEW OF MARKETING EXPERIENCE, DRUG USE AND SAFETY
- SUMMARY OF ADVERSE EXPERIENCE
- POISON RISK ANALYSIS

### V. SCIENTIFIC INVESTIGATIONS

- CLINICAL
- NONCLINICAL

**COMMENTS / SPECIAL INSTRUCTIONS:** DGP and OGD request your expertise in the review of the medication guides and REMS documents submitted for the products listed below. EDR links, where available, are provided for the submissions. In addition, package inserts, MGs, and REMS documents will be available in the GI eRoom (Safety folder, REMS/FDAAA Safety Labeling under review, metoclopramide subfolder). The class language that will be harmonized across the medication guides is the Boxed warning, and the Tardive Dyskinesia subsection under Warnings (this language is also provided in the supplement request letter sent to the sponsors). The REMS documents should also be fairly similar in that the REMS goal should be the same; however, sponsors may have different methods of distributing the medication guide. For the package insert, DGP requests only that DDMAC review the class language of the Boxed Warning and warnings section.

**ANDA 71-402ANI (oral syrup) submitted: 3/26/09 - insert, med guide, REMS (missing container label) \CDSESUB1\EVSPROD\ANDA071402\0001**

**ANDA 74-703Morton Grove (oral syrup) submitted: 3/26/09 - insert, med guide, REMS, container label \FDSWA150\NONECTD\74703\S 006\2009-03-26**
**ANDA 73-680** Silarx (oral syrup) submitted: 3/17/09 - insert, med guide, REMS (missing container label)
\CDSESUB\EVSPROD\ANDA073680\0002

**ANDA 72-744** Pharmaceutical Associates (oral syrup) submitted: 3/30/09 - med guide and REMS (missing insert and container label) - Not sure if this is electronic. OGD is waiting for their document room to check.

**NDA 17-854** Alaven (Reglan Tablets) submitted 3-25-09
Med Guide submission: S-051
The network location is: \FDSWA150\NONECTD\N17854\S_051\2009-03-25

REMS Submission: S-052
The network location is: \FDSWA150\NONECTD\N17854\S_052\2009-03-25

**NDA 21-793, Alaven (Reglan ODT)** submitted 3-25-09
Med Guide submission: S-004
The network location is: \FDSWA150\NONECTD\N21793\S_004\2009-03-25

REMS Submission: S-005
The network location is: \FDSWA150\NONECTD\N21793\S_005\2009-03-25

<table>
<thead>
<tr>
<th>SIGNATURE OF REQUESTOR</th>
<th>METHOD OF DELIVERY (Check one)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Everett/Joyce Korvick</td>
<td>☒ DFS</td>
</tr>
</tbody>
</table>

**PRINTED NAME AND SIGNATURE OF RECEIVER**

**PRINTED NAME AND SIGNATURE OF DELIVERER**
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Kristen Everett

4/6/2009 12:05:13 PM
16 April 2009

Gary J. Buehler, Director
Office of Generic Drugs, CDER
Food and Drug Administration
Metro Park North 4 (MPN 4), HFD-600
7519 Standish Place
Rockville, Maryland 20855

Re: ANDA 74-703 Metoclopramide Oral Solution USP, 5 mg/5 mL
Supplement No. 006; Proposed REMS - Amendment

Dear Mr. Buehler:

As the authorized regulatory agent for Wockhardt EU Operations (Swiss) A.G. ("Wockhardt EU"), Morton Grove Pharmaceuticals, Inc. ("MGP") hereby submits Supplement No. 006, Proposed REMS Amendment. This amendment is submitted in response to a telephone request from Ms. Sarah Park, FDA CDER Labeling Reviewer, on 15 April 2009 for a Microsoft Word version of the Proposed REMS submitted on 26 March 2009.

This submission is being made in duplicate. With each copy, I have enclosed a CD-ROM containing the REMS document in the Microsoft Word format. Each CD-ROM was prepared in accordance with FDA's guidance Providing Regulatory Submissions in Electronic Format – ANDAs dated June 2002. The enclosed CD-ROMs were scanned with Symantec/Norton anti-viral software, and they are virus free.

Please contact me for additional information required to process this amendment.

Sincerely,

Ralph J. Hodosh, PhD
Director, Regulatory Affairs
Tele: 847.410.6708 (New Number)
Email: rhodosh@mgp-online.com
Dear Sir:

We have received your supplemental new drug application submitted under section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

Name of Drug Product: Metoclopramide Oral Solution USP, 5 mg/5 mL

ANDA Number: 74-703/S-006

Date of supplement: March 26, 2009

Date of receipt: March 27, 2009

On February 26, 2009, we sent a letter invoking our authority under section 505(o)(4) of the FDCA to require safety related label changes to the labeling of Metoclopramide Oral Solution USP, 5 mg/5 mL to address the risk of tardive dyskinesia associated with the use of this product based on new safety information about this risk identified since the product was approved. You were directed to submit a prior-approval supplement proposing changes to the approved labeling in accordance with the above direction, or notify FDA that you do not believe a labeling change is warranted, and submit a statement detailing the reasons why such a change is not warranted.

On March 27, 2009, FDA received your prior-approval supplement that contained your proposed safety related labeling changes. Section 505(o) requires FDA to promptly review the supplement and, if we disagree with the proposed changes, to initiate discussions with you on the content of the changes. These discussions were to be completed within 30 days, unless FDA determined that an extension was warranted.

This letter is to inform you that we have determined that a 30-day extension of the discussion period is warranted to allow us to complete our review and reach agreement on the content of the labeling. Therefore, the discussion period for the supplement, ANDA 74-703/S-006, ends on May 26, 2009.
If you have questions, call Sarah Park, Labeling Reviewer, at (240) 276-8995.

Sincerely,

/See appended electronic signature page/

Gary Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Robert L. West
4/17/2009 02:58:49 PM
Deputy Director, for Gary Buehler
Good afternoon,

This email is in reference to your ANDA 74-703/S-006 for Metoclopramide Oral Solution USP, 5 mg/5 mL.

Please see the enclosed proposed changes to the Metoclopramide Oral Solution USP, 5 mg/5 mL package insert and Medication Guide. Please review the changes proposed by the Agency and incorporate accordingly.

If possible, please respond to the proposed changes as an amendment to the supplement by Tuesday, May 12, 2009. Please include a Word copy with your proposed Track Changes (if any).

Thank you,

Sarah Park

Sarah Park, Pharm.D.
Labeling Reviewer
Division of Labeling and Program Support
Office of Generic Drugs
Food and Drug Administration
240-276-8995
240-276-8999 (fax)
sarah.park@fda.hhs.gov

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW.

If you are not the addressee, or a person authorized to deliver this document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify us immediately by telephone at (301) 796-2120. Thank you.
12 May 2009

Gary J. Buehler, Director
Office of Generic Drugs, CDER
Food and Drug Administration
Metro Park North 4 (MPN 4), HFD-600
7519 Standish Place
Rockville, Maryland 20855

Re: ANDA 74-703 Metoclopramide Oral Solution USP, 5 mg/5 mL
Supplement No. 006; Proposed REMS – Amendment – Package Insert and Medication Guide Revisions

Dear Mr. Buehler:

As the authorized regulatory agent for Wockhardt EU Operations (Swiss) A.G. ("Wockhardt EU"), Morton Grove Pharmaceuticals, Inc. ("MGP") hereby submits Supplement No. 006, Proposed REMS Amendment. This amendment is submitted in response to an email request from Ms. Sarah Park, FDA CDER Labeling Reviewer, on 6 May 2009 for changes to the proposed package insert and medication guide.

This submission is being made in duplicate. With each copy, I have enclosed a CD-ROM containing the revised package insert and medication guide in both Microsoft Word and PDF formats. Each CD-ROM was prepared in accordance with FDA’s guidance Providing Regulatory Submissions in Electronic Format – ANDAs dated June 2002. The enclosed CD-ROMs were scanned with Symantec/Norton anti-viral software, and they are virus free.

Please contact me for additional information required to process this amendment.

Sincerely,

Ralph J. Hodosh, PhD
Director, Regulatory Affairs
Tele: 847.410.6708 (New Number)
Email: rhodosh@mgp-online.com
ANDA 74-703/S-006

Morton Grove Pharmaceuticals, Inc.
Attention: Ralph J. Hodosh, Ph.D.
Director, Regulatory Affairs
6541 West Main Street
Morton Grove, IL 60053

Dear Dr. Hodosh:

Please refer to your supplemental new drug application submitted under section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Metoclopramide Oral Solution USP, 5 mg/5 mL.

On February 26, 2009, we sent a letter invoking our authority under section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act (FDCA) to require safety related label changes to the labeling of Metoclopramide Oral Solution USP, 5 mg/5 mL to address the risk of tardive dyskinesia associated with the use of this product based on new safety information about this risk identified since the product was approved. You were directed to submit a prior approval supplement proposing changes to the approved labeling in accordance with the above direction, or notify FDA that you do not believe a labeling change is warranted, and submit a statement detailing the reasons why such a change is not warranted.

On March 27, 2009, FDA received your prior approval supplement that contained your proposed safety related labeling changes, including a Medication Guide. Section 505(o) requires FDA to promptly review the supplement and if we disagree with the proposed changes, to initiate discussions with you on the content of the changes. These discussions were to be completed within 30 days, unless FDA determined that an extension was warranted.

We refer to the letter we sent to you on April 17, 2009, informing you that we determined that a 30-day extension of the discussion period was warranted to allow us to complete our review and reach agreement on the content of the labeling.

This letter is to inform you that we have determined that an additional 30-day extension of the discussion period is warranted. Therefore, the discussion period for this supplement, ANDA 74-703/S-006, ends on June 25, 2009.
If you have any questions, please contact Sarah Park, Labeling Reviewer, at (240) 276-8995.

Sincerely,

{See appended electronic signature page}

Gary Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.

/s/
---------------------
Gary Buehler
5/18/2009 02:28:52 PM
10 June 2009

Gary J. Buehler, Director
Office of Generic Drugs, CDER
Food and Drug Administration
Metro Park North 4 (MPN 4), HFD-600
7519 Standish Place
Rockville, Maryland 20855

Re: ANDA 74-703 Metoclopramide Oral Solution USP, 5 mg/5 mL
Supplement No. 006; Proposed REMS – Amendment – Medication Guide Revisions

Dear Mr. Buehler:

As the authorized regulatory agent for Wockhardt EU Operations (Swiss) A.G. ("Wockhardt EU"), Morton Grove Pharmaceuticals, Inc. ("MGP") hereby submits Supplement No. 006, Proposed REMS Amendment. This amendment is submitted in response to an email request from Ms. Sarah Park, FDA CDER Labeling Reviewer, on 8 June 2009 for changes to the proposed medication guide.

This submission is being made in duplicate. With each copy, I have enclosed a CD-ROM containing the revised medication guide in both Microsoft Word and PDF formats. Each CD-ROM was prepared in accordance with FDA’s guidance Providing Regulatory Submissions in Electronic Format – ANDAs dated June 2002. The enclosed CD-ROMs were scanned with Symantec/Norton anti-viral software, and they are virus free.

Please contact me for additional information required to process this amendment.

Sincerely,

Ralph J. Hodosh, PhD
Director, Regulatory Affairs
Tele: 847.410.6708
Email: rhodosh@mgp-online.com
June 26, 2009

Sent Via E-mail and Federal Express

Gary J. Buehler, Director
Office of Generic Drugs, CDER
Food and Drug Administration
Metro Park North 4 (MPN 4), HFD-600
7519 Standish Place,
Rockville, MD 20855

Re: ANDA # 74-703 Metoclopramide Oral Solution, USP 5 mg/5 mL
Supplement No. 006; Proposed REMS – Amendment-Package Insert and Revised Medication Guide

Dear Mr. Buehler:

As the authorized regulatory agent for Wockhardt EU Operations (Swiss) A.G. ("Wockhardt EU"), Morton Grove Pharmaceuticals, Inc. ("MGP") hereby submits Supplement No. 006, Proposed REMS Amendment. This amendment is submitted in response to an email request from Ms. Sarah Park, FDA CDER Labeling Reviewer, on 24 June 2009 for changes to the proposed medication guide and package insert.

All changes to the medication guide are clearly identified in the side-by-side comparison that is included in this submission. This Labeling amendment is comprised of a CD-ROM, submitted in duplicate as the Archival copy and a Review copy, prepared in accordance with FDA's guidance, "Providing Regulatory Submissions in Electronic Format – ANDAs, "dated June 2002. There were no changes to the package, which is also included in the PDF format and Word format. The enclosed CD-ROMs were scanned with Symantec/Norton anti-viral software, and they are virus-free.

Please contact me for additional information required to process this amendment.

Sincerely,

Dominick DiPaolo
VP – Quality, Compliance & Regulatory Affairs
Email: ddipaolo@mgp-online.com
Telephone: 847-410-6725
Facsimile: 847-583-5052